8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 8-K

Current Report

Pursuant to Section 13 or 15(d) of

the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): March 10, 2013

Natus Medical Incorporated

(Exact name of registrant as specified in its charter)

000-33001

(Commission File Number)

Delaware	77-0154833
(State or other jurisdiction of incorporation)	(I.R.S. Employer Identification No.)

1501 Industrial Road

San Carlos, CA 94070

(Address of principal executive offices, with zip code)

650-802-0400

(Registrant’s telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

ITEM 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

On March 10, 2013 the Board of Directors of Natus Medical Incorporated approved the appointment of Jonathan Kennedy as Senior Vice President and Chief Financial Officer of the Company. In that capacity he will also serve as the principal financial officer and principal accounting officer of the Company. Mr. Kennedy will join the Company on April 8, 2013.

Mr. Kennedy, age 41, has served as Intersil Corporation’s Senior Vice President and CFO since April 2009. From December 2008 to April 2009, he was Intersil’s Interim CFO. From April 2005 to December 2008, he was Intersil’s Corporate Controller. From June 2004 to April 2005, he was Intersil’s Director of Finance. Prior to that time Mr. Kennedy served as Director of Finance and Information Technology of Alcon, Inc. from July 2000 to June 2004 and held various finance and information technology positions at Autonomous Technologies and Harris Corporation.

Mr. Kennedy entered into an employment agreement that is effective upon his joining the Company providing for initial compensation of an annual base salary of $350,000, participation in the Company’s cash bonus plan for 2013 with a target bonus of 65% of base salary, with a guaranteed payment of not less than the pro-rated target amount for 2013. In addition, he was awarded a signing bonus of $75,000. Mr. Kennedy will also receive options for the purchase of 110,000 shares of the Company’s common stock and 60,000 shares of restricted stock.

Steven J. Murphy, who has served as the Company’s Vice President Finance and Chief Financial Officer, and as principal financial officer and principal accounting officer, since 2003 will continue to serve as Vice President Finance.

ITEM 9.01. Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.	Description
99.1	Press release dated March 11, 2013 announcing the appointment of Jonathan Kennedy as Senior Vice President and Chief Financial Officer of the Company.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	NATUS MEDICAL INCORPORATED
	(Registrant)
By:	/s/ Steven J. Murphy
	Steven J. Murphy
	Vice President Finance and Chief Financial Officer

Dated: March 13, 2013

Exhibit Index

Exhibit No.	Description
99.1	Press release dated March 11, 2013 announcing the appointment of Jonathan Kennedy as Senior Vice President and Chief Financial Officer of the Company.

EX-99.1

Exhibit 99.1

Natus Appoints Jonathan Kennedy as Senior Vice President and Chief Financial Officer

SAN CARLOS, Calif. (March 11, 2013) – Natus Medical Incorporated (Nasdaq:BABY) today announced it has named Jonathan Kennedy, former Chief Financial Officer of Intersil Corporation (Nasdaq:ISIL), to the position of Senior Vice President and Chief Financial Officer.

Jonathan will report to Jim Hawkins, Chief Executive Officer, and oversee Natus Medical’s finance and administration, accounting, tax, and treasury functions. He will join Hawkins and John Buhler, President and Chief Operating Officer, on the Natus executive management team that is responsible for directing all aspects of the Company’s strategy, planning and operations.

“Jonathan is an excellent fit for the fast paced culture of Natus,” said Hawkins. “He is a dynamic financial leader with experience in both technology and medical device companies. The experience he has gained over the years in driving acquisition integration efforts, developing and implementing cost reduction initiatives on a worldwide basis, and evolving the finance function in growing enterprises positions him well for Natus.”

“I am pleased to join Natus during an exciting time in the Company’s evolution,” said Mr. Kennedy. “In just a few years, Natus has taken leadership roles in its markets and grown at an extraordinary pace. I look forward to being a part of its already successful team.”

Mr. Kennedy has been Senior Vice President and Chief Financial Officer of Intersil Corporation since April 2009. Prior to that, he was Intersil’s Corporate Controller since 2005 and Director of Finance since 2004. Before joining Intersil, Mr. Kennedy held management roles in Finance and IT with Alcon, Inc. and Harris Corporation. He holds a Bachelor of Science degree in Business Administration and a Master of Science degree in Accounting from the University of Central Florida. Mr. Kennedy also is a Certified Public Accountant.

Mr. Kennedy is expected to join Natus on April 8, 2013. At that time he will assume the CFO role currently held by Steven J. Murphy, who will remain with the Company as Vice President Finance, a position he has held since 2003. During Mr. Murphy’s tenure with the Company it has grown from $30 million in annual revenue to the current run rate of over $350 million.

About Natus Medical Incorporated

Natus is a leading provider of healthcare products used for the screening, detection, treatment, monitoring and tracking of common medical ailments in newborn care, hearing impairment, neurological dysfunction, epilepsy, sleep disorders, and balance and mobility disorders. Product offerings include computerized neurodiagnostic systems for audiology, neurology, polysomnography, and neonatology, as well as newborn care products such as hearing screening systems, phototherapy devices for the treatment of newborn jaundice, head-cooling products for the treatment of brain injury in newborns, incubators to control the newborn’s environment, and software systems for managing and tracking disorders and diseases for public health laboratories.

Additional information about Natus Medical can be found at www.natus.com.

COMPANY CONTACT:

Natus Medical Incorporated

Steven J. Murphy

Chief Financial Officer and Vice President Finance

(650) 802-0400

InvestorRelations@Natus.com